Discovery of Levesquamide B through Global Natural Product Social Molecular Networking

Mary M LeClair; Zacharie A Maw; Alyssa L Grunwald; Joshua R Kelly; Bradley A Haltli; Russell G Kerr; Christopher Cartmell

doi:10.3390/molecules27227794

Discovery of Levesquamide B through Global Natural Product Social Molecular Networking

Molecules. 2022 Nov 12;27(22):7794. doi: 10.3390/molecules27227794.

Authors

Mary M LeClair¹, Zacharie A Maw², Alyssa L Grunwald³, Joshua R Kelly³, Bradley A Haltli^{2

3}, Russell G Kerr^{1

2

3}, Christopher Cartmell^{1

4}

Affiliations

¹ Department of Chemistry, University of Prince Edward Island, 550 University Avenue, Charlottetown, PE C1A 4P3, Canada.
² Department of Biomedical Sciences, Atlantic Veterinary College, 550 University Avenue, Charlottetown, PE C1A 4P3, Canada.
³ Nautilus Biosciences Croda, 550 University Avenue, Charlottetown, PE C1A 4P3, Canada.
⁴ Antimicrobial Discovery Center, Department of Biology, Northeastern University, Boston, MA 02115, USA.

Abstract

Levesquamide A is an isothiazolinone-containing anti-tubercular natural product isolated from Streptomyces sp. RKND-216. Through the use of Global Natural Product Social Molecular Networking (GNPS), additional members of the levesquamide family were identified (B-G). Levesquamide B is a glycosylated analogue, isolated and structurally elucidated via spectroscopical techniques along with the putative structures of levesquamide C and D. For masses relating to the additional three levesquamides (E-G), their complete structures remain ambiguous.

Keywords: GNPS; Streptomyces; levesquamide; marine natural product.

MeSH terms

Biological Products* / chemistry
Streptomyces*

Substances

Biological Products

Grants and funding

M.M.L., Z.A.M., R.G.K. and C.C. was funded by Innovation PEI, Natural Sciences and Engineering Council of Canada, the Canada Research Chair Program, the Atlantic Canada Opportunities Agency, Canada Foundation for Innovation and the Jeanne and Jean-Louis Levésque Foundation. A.L.G., J.R.K. and B.A.H. was funded by Nautilus Biosciences Croda.